RxDoctor Payments Data

Bethany Bray, MD

Ophthalmology · West Columbia, SCNPI 1831222181

Payments from drug & device makers

$5,395in general payments, 2019–2025

Across 111 payments — averaging $48.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • AbbVie$1K
  • Sight Sciences, Inc.$629
  • NEW World Medical,inc.$386
  • Johnson & Johnson Surgical Vision, Inc.$333
  • Omeros Corporation$259
  • plus $491 from 9 others

What the payments were for

  • Food & beverage$5,376100%
  • Gifts$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,395 in reported general payments places this provider in the 70th percentile of 293 ophthalmology providers in South Carolina.

See all ophthalmology providers in South Carolina

Medicare billing

Part B allowed, 2024
$215,011
Medicare patients
504
Services billed
1,582

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine20$13,152
Prednisolone Acetate474$13,006
Ketorolac Tromethamine499$8,779
SimbrinzaBrinzolamide/Brimonidine Tart33$8,624
CequaCyclosporine11$5,673
Cyclosporine15$5,195
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol18$3,130
LumiganBimatoprost11$2,955
TafluprostTafluprost/Pf15$1,592
Tobramycin-DexamethasoneTobramycin/Dexamethasone38$1,378
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat53$937
Latanoprost132$758
Fluorometholone14$738
Timolol Maleate46$454
ValacyclovirValacyclovir Hcl11$376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$1,400$16,10731 claims
AlconSimbrinza$1,899$8,62433 claims
Sun Pharmaceutical Industries Inc.Cequa$58$5,67311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 293 ophthalmology providers in South Carolina.

Other ophthalmology in West Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →